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1. Abstract

The early growth response (Egr) family of transcription factors is composed of four members
Egr1-4, which play roles in various cell behaviors including proliferation, apoptosis, and
differentiation in a cell type and stimulus specific manner. Roles for Egr1-3 are especially well
documented in the nervous system: Egr 1 and 3 regulate expression of genes involved in
synaptic plasticity and long term potentiation, Egr2 contributes to hindbrain development
and peripheral nerve myelination, and Egr 1 and 2 also contribute to the transcriptional
network that drives neuronal differentiation in PC12 cells. However, the mechanisms that
regulate Egr activity are not fully understood. One mechanism of Egr regulation involves
interactions with coregulators NGFI-A binding protein 1 and 2 (Nab1 and Nab2). Most studies
demonstrate that Nab1 and 2 repress Egr transactivation when bound; however, one report
indicates Nabs can enhance Egr transactivation in a target gene-specific manner. As such, the
molecular mechanism controlling the effect of Nabs on the activity of Egr1-3 remain unclear.
Here, we provide evidence that Nab2 is rapidly phosphorylated in PC12 cells following
treatment with nerve growth factor (NGF) based on an upward mobility shift in Western blot
that is reversed by phosphatase treatment. The mobility shift was inhibited by the mitogenactivated protein kinase kinase (MEK) inhibitor (UO126), indicating Nab2 phosphorylation is
mediated at least in part by extracellular-regulated kinase (ERK). Nine sites on Nab2 that
match the consensus sequence for ERK phosphorylation were identified and site-directed
mutagenesis was conducted to generate alanine mutants for each. Unexpectedly, exogenous
Nab2 was constitutively phosphorylated independent of NGF treatment; nevertheless, the
Nab2-S126A, -S129A, -S138A, T157A, and -T401A mutants exhibited downward mobility
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shifts, indicating they are likely phosphorylation sites. Mammalian two-hybrid assays were
then conducted to detect Nab2-Egr1 interactions and to evaluate whether the mutation of
each of the phosphorylation sites affect their interactions. Experiments thus far have tested
the effect of three Nab2 phosphorylation site mutants (S126A, T157A, and S401A), none of
which affect Nab2 interactions with Egr1.
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2. Introduction
2.1 Egr family members are transcription factors
The Egr family of transcription factors are immediate-early genes and consist of four members:
Egr1 (also known as NGFI-A, Krox-24, Zif-268, Znf225, AT225, G0S30, TIS8), Egr2 (also known as
Krox-20, AT591, CMT1D, and CMT4E), Egr3 (also known as PILOT), and Egr4 (also known as NGIFC, and pAT133). Egr family members contain a conserved DNA binding domain, which is
composed of three tandem Cys2-His2-type zinc-finger motifs at the carboxyl terminus (figure 1)
(Christy and Nathans 1989; Pavletich and Pabo 1991). The zinc-finger domain is structured as an
antiparallel beta pleated sheet and an alpha helix that are held together by a zinc atom and
hydrophobic residues (figure 2) (Gashler and Sukhatme 1995). There is ninety-percent homology
within the DNA binding domain of Egr family members, suggesting they bind similar DNA
sequences and/or similar target genes. Egr family members bind to DNA sequences that are GCrich and contain the nine base pair consensus site: 5’-GCG(G/T)GGGCG-3’ (Christy and Nathans
1989; Nardelli et al. 1991; Patwardhan et al. 1991; Cao et al. 1993). Unlike the carboxyl-terminus,
the amino terminus of Egr family members is variable. Despite this variability, all Egr family
members contain an activation domain at the amino terminus through which they activate target
genes, and the activation domain of Egr1 has been the best characterized (Thiel et al. 2000). Egr13 also contain a conserved repression (R1 domain). NGFI-A binding proteins (Nab1 and Nab2)
have been shown to bind to the R1 domain and negatively regulate the transcriptional activity of
Egr1-3 (Russo et al. 1995; Svaren et al. 1996; Thiel et al. 2000).
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2.2 Induction of Egr family members and their role in the nervous system
Egr family members are induced in response to several stimuli, including growth factors,
cytokines, neurotransmitters, as well as cell stressors such as hypoxia and oxidative stress
(O'Donovan et al. 1999; Pagel and Deindl 2012; Thiel et al. 2014). After induction, Egr proteins
contribute to several different cell behaviors including differentiation, proliferation, and
apoptosis in a cell-type and stimulus-type specific manner (Khachigian et al. 1997; Lee et al. 2004;
Pagel et al. 2012). Roles of Egr proteins are particularly well documented in the nervous system.
One of the original characterizations of Egr1 stemmed from studies on the neuronal
differentiation of PC12 cells in response to NGF (Milbrandt 1987). PC12 cells are a frequently
utilized model to investigate the molecular mechanism of neuronal differentiation. Following
NGF treatment, PC12 cells develop several features that are characteristic of neurons, such as
cessation of cell proliferation, up-regulation of neuronal genes, neurite outgrowth, and
development of electrical excitability (Greene and Tischler 1976). Egr1 is induced within 1 hour
of NGF treatment and is required for subsequent differentiation, as expression of a dominantnegative Egr blocks differentiation in response to NGF (Levkovitz et al. 2001). Although not fully
characterized, several Egr1 transcriptional targets that contribute to differentiation have been
identified, including p35, Arc, Vgf, Sik1, Phlda1, Kctd11, kdm6b, Hbegf, and Ankrd34c (Harada et
al. 2001; Adams et al. 2017).
Another role for Egr1 was discovered from the observation that induction of long term
potentiation (LTP) in the dentate gyrus of the hippocampus is associated with the rapid induction
and activation of Egr1 (Cole et al. 1989; Wisden et al. 1990). Egr1 was later shown to play a critical
role in LTP when Egr1 mutant mice could not maintain LTP induction in the dentate gyrus for
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longer than 24 hours (Jones et al. 2001). More recently, overexpression of Egr1 in the forebrain
of transgenic mice was shown to enhance LTP in the dentate gyrus (Penke et al. 2014). Egr3 is
also essential for normal LTP and for hippocampal and amygdala-dependent learning and
memory, as Egr3-deficient mice have profound defects in hippocampal LTP as well as
hippocampal and amygdala dependent learning and memory (Li et al. 2007). Egr2 mRNA is also
upregulated in the hippocampus in response to LTP, but it is not associated with increased
protein levels, suggesting that Egr2 may not play a role in LTP or LTP-associated learning a
memory (Cheval et al. 2012).
Although the role of Egr2 in LTP is unclear, Egr2 is important in hindbrain development.
Egr2 is expressed in specific hindbrain nuclei in early development of the mouse brain (Wilkinson
et al. 1989). Egr2 is part of a transcriptional cascade that regulates Hox gene expression which is
necessary for proper segmentation of the hindbrain during development (Sham et al. 1993).
Moreover, Egr2 mutant mice die within two weeks after birth because of improper segmentation
in the hindbrain during development (Schneider-Maunoury et al. 1993).
Egr2 is also involved in peripheral nerve myelination. Peripheral myelinating cells
(Schwann cells) express Egr2 before the onset of myelination and transgenic mice with mutant
Egr2 have improperly differentiated Schwann cells and incomplete myelination of peripheral
axons (Topilko et al. 1994). Egr2 expression is maintained in mature myelinating cells (Zorick et
al. 1996), and the maintenance of peripheral nerve myelination requires continuous Egr2
expression, as Egr2 knockout mice have hypomyelinated nerves at 4 and 6 weeks of age (Decker
et al. 2006). In humans, patients with congenital hypomyelinating neuropathy (CHN) contain one
dominant or two recessive mutations in Egr2 (Warner et al. 1998). Further, the severity of patient
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symptoms in human myelinopathies is directly correlated with the inability of a mutant Egr2 to
bind DNA (Warner et al. 1999).

2.3 Post-translational regulation of Egr family members
Egr family members can be modified by a variety of post-translational modifications. Mechanisms
of post-translational modification have been best characterized in Egr1. Egr1 contains a number
of O- and N-linked glycosylation sites, but little is known about their role except that one N-linked
glycosylation within the DNA binding domain may regulate Egr1 binding (Muller et al. 1991). Egr1
is phosphorylated by casein kinase II, tyrosine kinases, and protein kinase C, all of which increase
the half-life of Egr1 and its DNA binding activity (Cao et al. 1992; Cao et al. 1993; Huang et al.
1998). In addition, Egr1 is phosphorylated by Akt at two sites (S350 and T309), which is necessary
for subsequent Egr1 sumoylyation by ARF/sumoylyation ligase (Yu et al. 2004; Yu et al. 2009).
One study showed that sumoylyation of Egr1 triggered its ubiquitination and consequent
degradation (Manente et al. 2011). Lastly, Egr1 contains an acetylation site within its DNA binding
domain that can be acetylated by the p300/CBP complex, which reduces transcriptional activity
of Egr1 (Yu et al. 2009).
2.4 NGFI-A Binding Proteins (Nab1 and Nab2) are corepressors of Egr1-3
In addition to post-translational modification, Egr1-3 are regulated through protein-protein
interactions with coregulators Nab1 and Nab2. Nab1 was first identified by its interaction with
Egr1 and Egr2 in a yeast two-hybrid screen (Russo et al. 1995). In this study, Nab1 repressed
transactivation of Egr1 but had no effect on Egr3 activity. Nab2 was later identified as a protein
with high homology to Nab1 in two domains (figure 3), termed Nab conserved domain 1 (NCD1)
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and 2 (NCD2) (Svaren et al 1996). Nab2 similarly acts as a transcriptional corepressor of Egr1-3.
Nab1 and Nab2 interact with Egr1-3 via the R1 domain (Svaren et al. 1998). Nab corepression of
Egr1-3 transactivation also involves the recruitment of other proteins. Nab2 interacts with
chromatin helicase DNA-binding protein 4 (CHD4) through its CHD4-interacting domain (CID)
(Srinivasan et al. 2006). CHD4 is a subunit of the nucleosome remodeling and deaceteylase
(NuRD) complex, which represses transcription via histone decaceteylation and nucleosome
mobilization.
Although there is much data suggesting that Nab corepressors play a critical role in
regulation of Egr activity, whether there are molecular mechanisms that govern interactions
between Nab1-2 and Egr1-3, as well as the effect of Nab on Egr activity upon binding, is largely
unknown. This study extends our understanding of additional mechanisms that regulate Nab2
and potentially Egr function.
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3. Materials and Methods
3.1 Mammalian cell culture
Human brain neuroglioma (H4) cells, rat adrenal medulla pheochromocytoma (PC12) cells, and
human cervical cancer (HeLa) cells were grown and maintained for experimentation. H4 and HeLa
cells were maintained in growth medium consisting of Dulbecco’s modification of Eagle’s
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C and 10% CO2. PC12
cells were maintained in growth medium consisting of DMEM supplemented with 10% FBS and
5% horse serum (HS) at 37°C and 10% CO2. For Western blot experiments, 5 x 105 PC12 or H4
cells were plated per 60 mm dish in 4 mL of growth medium and incubated for 24-48 hours until
cell harvest. For luciferase assays, 106 PC12 or 5 x 105 HeLa cells were plated per well of a 6-well
cell culture dish in 2 mL of growth medium and incubated for 24-48 hours until cell harvest.
3.2 Generating Nab2 phosphorylation site mutants
An expression construct containing Nab2 cDNA (pJDM-Nab2) was received from Jeffrey
Milbrandt at Washington University School of Medicine in St. Louis. The Nab2 cDNA was
subcloned into the expression vector pcDNA3 (pcDNA3-Nab2) by Kenneth Adams and Sergey
Kletsov. An oligonucleotide encoding a FLAG tag was also inserted at the 3’ end of the Nab2 cDNA,
resulting in a pcDNA3-Nab2-FLAG construct. To generate Nab2 phosphorylation site mutants,
site-directed mutagenesis (SDM) reactions were performed on pcDNA3-Nab2-FLAG to change
codons for serine/threonine that are situated immediately upstream of a proline residue to
alanine. SDM reactions were performed to generate nine single site mutants: S114A, S126A,
S129A, S138A, T157A, S172A, S176A, T401A, and S446A. Additional SDM reactions were
performed to generate three double mutants (S126A/S129A, S126A/T401A, and S129A/T401A)
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and one triple mutant (S126A/S129A/T401A). All SDM reactions were performed using Agilent
Technologies QuikChange II XL site-directed mutagenesis kit (Agilent Technologies, 200515-5)
according to manufacturer’s instructions.
Following SDM, XL-10 Gold Ultracompetent cells (Agilent Technologies, 200517-4) were
transformed with the products of each SDM reaction according to manufacturer’s instructions
and spread onto Luria-Bertani (LB) agar plates supplemented with ampicillin at 100 µg/mL.
Clones from each transformation were isolated and inoculated in 6 mLs of LB broth containing
Ampicillin at 100 µg/mL. The mutant Nab2 constructs were then purified from broth culture by
using the QIAprep Spin Miniprep Kit (Qiagen, 27106) according to manufacturers’ instructions.
To confirm mutagenesis of pcDNA3-Nab2-FLAG at each site, 200-300 ng/µL samples of each
construct were sent to Eurofins for sequencing using a SP6 or a T7 primer. After confirmation of
mutagenesis by sequencing, 200 mL of LB Broth containing Ampicillin at 100 ng/mL were
inoculated with 200 µl of cultures grown for miniprep, and the mutant Nab2 constructs were
then purified from broth culture by using the QIAprep Spin Maxiprep Kit (Qiagen, 12163)
according to manufacturers’ instructions.
3.3 Cell Transfection
For Western blot experiments, PC12 (106/60 mm plate), and H4 cells (5 x 105/60 mm plate) were
plated 24 hours before transfection. Transfection mixtures were prepared containing 500 µl
DMEM, 10 μl of TransIT-LT1 reagent (Mirus, MIR 2300), and 2 μg of plasmid DNA. The mixtures
were then incubated for 15-30 min before application to appropriate mammalian cell cultures.
For luciferase assay, PC12 cells (106/well) or HeLa cells (5 x 105/well) were plated 24 hours before
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transfection. Transfection mixtures were prepared containing 250 µl DMEM, 5 μl of TransIT-LT1
reagent (Mirus), and 1-2 μg of total plasmid DNA. The mixtures were then incubated for 15-30
min before application to each well of the appropriate mammalian cell line. After application of
transfection mixtures, cultures were incubated at 37°C, 10% CO2 for 24-48 h before harvest.
3.4 Cell harvest and Western blot analysis
Cells were washed twice with 1X phosphate-buffered saline (PBS), lysed directly in 200-300 μl of
Laemmli buffer, and heated to 100°C for 5 min. Ten to twenty μl of each lysate were loaded and
electrophoresed through 10 % SDS-polyacrylamide gels, transferred to nitrocellulose
membranes, and Western blot conducted to detect Nab2-FLAG phosphorylation mutants with
mouse anti-FLAG (Sigma, F3165, 1:10,000) alongside β-actin with mouse anti-actin antibodies
(Sigma, A5441, 1:20,000 dilution) as a loading control. Membranes were submerged in blocking
buffer (5% nonfat dried milk in TBS + 0.2% Tween-20) for 30 min at room temperature, after
which they were incubated with primary antibody diluted in blocking buffer for 12–18 h at 4°C.
Membranes were then washed three times for 1 hour in TBS + 0.2% Tween-20 and incubated
with secondary antibody (goat anti-mouse HRP-conjugate, Bio-Rad, 170–6516, 1:3000 dilution)
diluted in blocking buffer for 1–2 h at room temperature. Membranes were washed three times
for 1 hour in TBS + 0.2% Tween-2. Bands were then detected by incubation in chemiluminescence
reagent followed by exposure to X-ray film (Western Lightning Plus-ECL, Enhanced
Chemiluminescence Substrate, Perkin Elmer, NEL105001).
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3.6 Mammalian two-hybrid assay
Reporter and expression constructs used for mammalian two-hybrid assays were received from
Dr. John Svaren at the University of Wisconsin-Madison and included (1) a luciferase reporter
construct with four upstream Gal4 binding sites (Gal4 reporter), (2) an expression construct
encoding the Egr1 R1 domain fused to the Gal4 DNA binding domain (R1-DBD), and (3) an
expression construct encoding full length Nab2 fused to the Gal4 activation domain (Nab2-VP16).
HeLa cells were transfected with 1-2 μg of a total plasmid DNA that consisted of varying
combinations of: pcDNA3, Gal4 reporter, R1-DBD, Nab2-VP16, and/or Nab2-VP16
phosphorylation site mutants (phosphorylation mutants were prepared as previously described
in generating Nab2 phosphorylation site mutants and sequencing was performed as previously
described but with a CMV forward primer). Cells were harvested 24-48 hours after transfection,
rinsed once in ice cold 1X phosphate-buffered saline, and resuspended in 100 μL of lysis buffer
(0.1 M potassium phosphate, pH 7.8, 1% Triton X-100, 1 mM dithiothreitol, 2 mM EDTA). The
samples were vortexed briefly, incubated on ice for 15 min, and centrifuged in a for 1 min at
maximum speed to remove cellular debris. The supernatant was then collected and 30 μL of each
sample was loaded in triplicate in a 96-well plate. Immediately prior to measurement of
luminescence, 100 μL of assay buffer was added to each well (30 mM Tricine, 3 mM ATP, 15 mM
MgSO4, 10 mM dithiothreitol, 1 mM D-luciferin, pH 7.8). Luminescence was measured using an
integration time of 10 seconds using a Synergy II Biotek plate reader with Gen5 software. The
raw luminescence from two of the triplicate wells were selected and used to calculate the
average luminescence of each sample. Raw values were converted into fold induction by dividing
the raw luminescence of the sample (reporter/R1-DBD, reporter/ Nab2-VP16 or reporter/R1-
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DBD/Nab2-VP16) by the raw value of luminescence from reporter alone. Each experiment was
repeated three times and the p-value (p < 0.001) was calculated using one-tailed students t-test.
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4. Results
4.1 Nab2 exhibits a transient mobility shift following NGF treatment
During a previous study investigating the role of Nab2 in neuronal differentiation of PC12 cells,
Western blot analysis showed an unexpected mobility shift of Nab2 following NGF treatment
(figure 4). In the experiment, PC12 cells were treated with NGF for 0-6 hours and subjected to
Western blot. The upward mobility shift was detected by 1 h, after which the shift gradually
returned to baseline between 2-6 hours following NGF treatment, suggesting that NGF treatment
induces a transient post-translational modification of Nab2 in PC12 cells.
Although the data presented in figure 4 suggests that Nab2 is post-translationally
modified in response to NGF, another possibility is that the upper molecular weight bands
detected after 1 hour of NGF treatment represent newly synthesized Nab2 protein that is larger
than pre-existing Nab2 in untreated cells. While growth factors induce post-translational
modification of numerous proteins, they also induce Nab2 transcription and up-regulate global
protein synthesis rates. Thus it was important to discern whether the upper molecular weight
Nab2 bands resulted from post-translational modification of pre-existing Nab2 or synthesis of
Nab2 in a larger (perhaps precursor) form. To test this possibility, Western blot analysis was
performed on PC12 cells treated with NGF in the presence of cylcoheximide (CHX), which inhibits
global protein synthesis (figure 5). Nab2 exhibited an upward mobility shift both in the presence
and absence of CHX, confirming that NGF induces post-translational modification of pre-existing
Nab2. However, Nab2 levels were higher in the absence of CHX, suggesting that induction of
Nab2 expression is occurring at the same time as post-translational modification.
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4.2 Endogenous Nab2 mobility shift is due to ERK-mediated phosphorylation
A variety of post-translational modifications could account for the Nab2 mobility shift (e.g.
phosphorylation, ubiquitination, and sumoylyation). To evaluate if phosphorylation is the cause
of the Nab2 mobility shift in response to NGF treatment, PC12 cells were treated with NGF for
either 10 minutes or 1 hour, lysed, and the cell lysates were treated with lambda protein
phosphatase prior to Western blot analysis (figure 6). The phosphatase induced a downward
mobility shift of Nab2 in untreated PC12 cells, suggesting that Nab2 is basally phosphorylated in
the absence of NGF. Treatment with NGF for 10 minutes or 1 hour induced similar upward
mobility shifts that were reversed by phosphatase treatment, suggesting that the shifts are due
to phosphorylation.
Previous research has demonstrated that NGF treatment activates two cell signaling
pathways: (1) Ras/Raf/MEK/ERK and (2) PI-3 kinase/Akt (figure 7). To determine if ERK signaling
and/or PI-3 kinase signaling are responsible for Nab2 phosphorylation in response to NGF, the
effects of a MEK inhibitor (UO126) and a PI-3 kinase inhibitor (LY294002) on the Nab2 mobility
shift in response to NGF treatment were examined. PC12 cells were pre-treated with UO126 or
LY294002 for 30 minutes before NGF treatment for an additional 10 minutes or 1 hour. In
addition, treatments were done in the presence and absence of CHX to ensure that any observed
mobility shift was not due to differences in Nab2 expression. Following treatments, the cells were
harvested and subjected to Western blot analysis to evaluate Nab2 mobility (figure 8). UO126
treatment inhibited the Nab2 mobility shift induced by NGF treatment for 10 minutes or 1 hour
both in the presence and absence of CHX. LY294002 did not inhibit the Nab2 mobility shift in
either the presence or absence of CHX. This suggests that ERK signaling is necessary for Nab2
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phosphorylation and that PI-3 kinase/Akt signaling does not mediate Nab2 phosphorylation in
PC12 cells treated with NGF.
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4.3 Exogenous Nab2 is constitutively phosphorylated independent of ERK
Having demonstrated that endogenous Nab2 is phosphorylated in PC12 cells, subsequent
experiments focused on identifying specific phosphorylation sites on Nab2 by performing
mutagenesis and transfection. However, before mutating Nab2, the mobility patterns of
exogenous Nab2 prior to and after NGF treatment were examined alongside the effect of
phosphatase treatment. An expression construct containing the Nab2 cDNA (pJDM-Nab2) was
generously donated by Dr. Jeffrey Milbrandt at Washington University, St. Louis. PC12 cells were
either untransfected or transfected with pJDM-Nab2 and then treated with NGF for 10 minutes
(figure 9). Cell lysates were harvested, treated with phosphatase, and Western blot was
performed. As expected, NGF induced an upward mobility shift of endogenous Nab2 which was
reversed by phosphatase treatment. However, NGF treatment does not induce an upward
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mobility shift of exogenous Nab2, indicating that either NGF does not does not induce
phosphorylation of exogenous Nab2 or NGF-induced phosphorylation does not cause a mobility
shift. Phosphatase treatment of transfected lysates with or without NGF treatment caused a
downward mobility shift, indicating that exogenous Nab2 is constitutively phosphorylated when
expressed in PC12 cells.
The basal phosphorylation state of exogenous Nab2 was unexpected. To determine if
serum starvation is necessary to reduce the phosphorylation state of exogenous Nab2, cells were
transfected with empty vector or pcDNA3-Nab2-FLAG and serum starved for 0-2 days. Cell lysates
were harvested and western blot analysis was performed using an anti-FLAG antibody (figure 10).
A quadruplet banding pattern of Nab2 was observed and the banding pattern was consistent
throughout 0-2 days of serum starvation. This data suggests that exogenous Nab2 is basally
phosphorylated independent of growth factors.
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4.4 Identification of nine putative phosphorylation sites on Nab2
The mobility shift of endogenous Nab2 in response to NGF combined with the downward mobility
shift of endogenous and exogenous Nab2 induced by phosphatase treatment provide strong
evidence that Nab2 is phosphorylated under basal conditions and further phosphorylated in
response to NGF treatment. Data from figure 6 indicate that phosphorylation of endogenous
Nab2 is ERK mediated, but these results could not be replicated with exogenous Nab2 on account
of the observed constitutive phosphorylation of Nab2 after transfection (figure 10). Despite this
discrepancy, serine and threonine residues on Nab2 that matched consensus sites for ERK
phosphorylation were identified as candidate ERK phosphorylation sites. ERK is a proline-directed
kinase that preferentially phosphorylates serine and threonine residues that lie directly upstream
of a proline residue (i.e., S/TP sites), with a stronger preference for PXS/TP sites. Nab2 contains
nine S/TP sites (S114, S126, S129, S138, T157, S172, S176, T401 and S446), two of which match
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the PXS/TP consensus sequence (S129 and S176). Site directed mutagenesis was performed on
pcDNA3-Nab2-FLAG at the codon for each of the indicated residues to change the codon for
serine/threonine to a codon for alanine (table 1). Samples of each mutant plasmid were
subjected to Sanger sequencing to confirm successful mutation (figure 11).
After confirmation of mutagenesis by sequencing, each single site mutant of pcDNA3Nab2-FLAG (S114A, S126A, S129A, S138A, T157A, S172A, S176A, T401A, and S446A) was
transfected into PC12 cells alongside wild-type. Cell lysates were harvested and Western blot
analysis performed using an anti-FLAG antibody to evaluate the effect of the mutation(s) on the
mobility patterns of exogenous Nab2 (figure 12). Several mutants exhibited an altered banding
pattern compared to the quadruplet band pattern of wild-type Nab2-FLAG. Of the nine mutants,
the S126A, S129A, and T401A exhibited the greatest change, with bands that migrated alongside
the lower molecular weight bands of wild-type Nab2 FLAG. The S129A mutant also exhibited a
similar band collapse but it did not appear to be as significant as that seen in S126A and T401A.
After observing the effect of S126A, S129A, and T401A on Nab2 mobility, double and
triple mutants of pcDNA3-Nab2-FLAG at these sites were generated by site-directed
mutagenesis, which were again confirmed by Sanger sequencing (data not shown). Each double
and triple mutant (S126A/S129A, S16A/T401A, S129A/T401A, and S126A/S129A/T401A) was
transfected into PC12 cells alongside wild-type pcDNA3-Nab2-FLAG, followed by harvest and
Western blot analysis with anti-FLAG antibody (figure 13). As in previous experiments, the single
site mutants exhibited similarly collapsed banding patterns. The S126A/S129A double mutant did
not yield a greater band collapse, while the double mutants with T401A both exhibited greater
collapse. The triple mutant exhibited the greatest band collapse, yielding a single band that
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migrated similarly to the lowest molecular weight band detected in the wildtype Nab2-FLAG
transfections. This data indicates Nab2 is likely phosphorylated at multiple sites, each of which
contributes to altered mobility of Nab2 in Western blot.
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4.5 Evaluation of the effect of Nab2 phosphorylation on Nab2/Egr1 interactions using mammalian
two-hybrid assay
After demonstrating that Nab2 is phosphorylated and identifying potential phosphorylation sites
on Nab2, mammalian two-hybrid assays were used to determine whether Nab2 phosphorylation
affects its ability to form protein-protein interactions with Egr1. The assay entails transfecting
cells with three constructs: (1) a luciferase reporter with four upstream Gal4 binding sites
(reporter), (2) an expression construct encoding the Egr1 R1 domain fused to the Gal4 DNA
binding domain (R1-DBD), and (3) an expression construct encoding full length Nab2 fused to the
Gal4 activation domain (Nab2-VP16). Following transfection, the R1-DBD fusion protein will bind
the reporter; if Nab2-VP16 then binds the R1 domain, it will bring the VP16 domain to the
reporter, resulting in luciferase expression, which can be detected and quantified by luciferase
assay using a luminometer.
To first demonstrate Nab2/Egr1 interactions, HeLa cells were transfected with reporter
alone, reporter + R1-DBD, reporter + Nab2-VP16, or reporter + R1-DBD + Nab2-VP16. Cells were
then harvested and subjected to luciferase assay to quantify relative luciferase expression levels.
Luminescence levels from cells transfected with reporter + R1-DBD + Nab2-VP16 increased
approximately 60-fold compared to reporter alone when 1 ug of total DNA was transfected and
135-fold when 2 ug of total DNA was transfected (Figure 14). This data suggests that the R1-DBD
and Nab2-VP16 are interacting and activating transcription to the luciferase reporter, thus
indicating that the mammalian two-hybrid is working successfully.
After ensuring that the mammalian two-hybrid could be used to measure interactions
between Nab2 and the R1 domain of Egr1, mutagenesis was performed on the Nab2-VP16
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construct in order to use the mammalian-two hybrid assay as a model for investigating the effect
of Nab2 phosphorylation on its interaction with Egr1. Three single site phosphorylation mutants
(S126A, T157A, and S401A) of Nab2-VP16 construct were generated using site-directed
mutagenesis and confirmed by Sanger sequencing as previously described (figure 15). HeLa cells
were then transfected with reporter alone, reporter + R1-DBD, reporter + Nab2-VP16 wild-type,
reporter + R1-DBD + Nab2-VP16 wild-type/S126A/T157A/S401A. Cell were then harvested and
subjected to luciferase assay. Luminescence from cells transfected with reporter + R1-DBD +
wild-type Nab2-VP16 increased approximately 300-fold compared to reporter alone.
Luminescence from cells transfected with reporter, R1-DBD, and single site Nab2-VP16
phosphorylation mutants (S126A/T157A/T401A) also increased approximately 250-300 fold
compared to reporter alone, which did not significantly differ from wild-type Nab2. Altogether,
this data confirms that protein-protein interactions between Nab2 and the Egr1 R1 domain can
be detected by the mammalian two hybrid assay and indicates that the interaction is not affected
by phosphorylation at S126, T157, and T401 on Nab2.
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5. Discussion
This study demonstrates that the transcriptional coregulator Nab2 is transiently phosphorylated
in PC12 cells in response to NGF in an ERK-dependent manner. NGF induced an upward mobility
shift of Nab2 in Western blot within 10 minutes of treatment, which was reversed by incubating
cell lysates with lambda protein phosphatase and was inhibited by pre-treatment with a MEK
inhibitor U0126. The upward mobility shift of Nab2 in response to NGF was not reversed by the
PI3K inhibitor LY249002.
Given the effect of NGF treatment on endogenous Nab2, we expected to observe the
same transient upward mobility shift of exogenous Nab2 following NGF treatment. However,
Western blot did not show an upward mobility shift of exogenous Nab2 in response to NGF;
instead, exogenous Nab2 migrated as a quadruplet of bands ranging in size from the lowest
molecular weight band of endogenous Nab2 before NGF treatment to the highest molecular
weight band after NGF treatment. Nevertheless, lambda phosphatase treatment of lysates from
transfectants caused a downward shift of exogenous Nab2 to a molecular weight similar to that
of endogenous Nab2 before NGF treatment. These data suggest that exogenous Nab2 is basally
phosphorylated. Serum starvation inhibited ERK activity based on levels of ERK phosphorylation,
but had no effect on the exogenous Nab2 banding pattern, suggesting that phosphorylation of
exogenous Nab2 may be ERK-independent.
Despite the discrepancy in endogenous versus exogenous Nab2 band shifts, potential ERK
phosphorylation sites were investigated. ERK is a proline-directed kinase that phosphorylates
serine or threonine residues that lie directly upstream of a proline residue. Nine potential ERK
consensus sites were identified within the Nab2 sequence: S114, S126, S129, T157, S172, S176,
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T401, and S446. After site-directed mutagenesis of each serine/threonine residue to alanine and
transfection of mutant constructs into PC12 cells, Western blot showed a change in Nab2 banding
pattern in five phosphorylation mutants: S126A, S129A, S138A, T157A, and T401A. The greatest
change in banding pattern was seen in the S126A, S129A, and T401A mutants. Double and triple
phosphorylation mutants at these three sites (S126A/S129A, S126A/S401A, S129A/S401A,
S126A/S129A/S401A) depicted an additive effect on the banding pattern change of Nab2 in
Western blot. Of the five phosphorylation mutants that affected the Nab2 banding pattern, four
lie between the NCD1 and NCD2 domain (S126A, S129A, S138A, T157A) and one is in the CID
domain (T401A). The area between NCD1 and NCD2 does not have a characterized function, but
the CID domain modulates Nab2 interaction with CHD4 and the NuRD complex. The Nab2-T401A
mutant may affect Nab2’s ability to interact with CHD4, which would be an interesting area for
further study.
After identifying potential sites of ERK-mediated phosphorylation on Nab2, we examined
whether Nab2 phosphorylation at these sites would affect its ability to interact with Egr1 using a
mammalian two-hybrid assay. We first showed that mammalian two-hybrid assay is capable of
detecting interaction between wild-type Nab2 and the R1 domain of Egr1, and optimized
conditions for this protocol. We then used site-directed mutagenesis to generate four mutants
of the Nab2 construct (S126A, T157A, and T401A) and evaluated the effect that the mutation had
on Egr1 interactions. We found that the interaction between the R1 domain of Egr1 and the
phosphorylation mutants did not differ from wild-type Nab2. These findings need to be further
investigated because consistent clones were not able to be used for experimentation with the
phosphorylation mutants which could have caused the high variability in luciferase fold induction
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in the experiments which accounted for the high standard deviation. Nab2-S129A and -S138A
mutants for mammalian two-hybrid analysis also needs to be generated and evaluated for any
effect on interactions with the Egr1 R1 domain. Lastly, mammalian two-hybrid assays conducted
thus far have not included co-transfection with a β-galactosidase expression construct to
normalize luminescence data for transfection efficiency, which will be included in future
experiments.
It is possible that phosphorylation of Nab2 affects its interactions with proteins other than
Egr1. For example, Nab2 interacts with the CHD4 domain of the NuRD complex, which modulates
transcriptional repression. Nab2 phosphorylation could potentially alter Nab2 binding to CHD4,
and this could effect transcriptional repression done by the NuRD complex. In addition,
phosphorylation of Nab2 could affect Nab2’s interactions with other Nab proteins (Nab1 and
Nab2). Nab2 can multimerize with Nab1 or Nab2 through the NCD1 domain, but Nab2
phosphorylation could modify this interaction. Furthermore, Nab2 has been primarily
characterized as a corepressor of Egr1, but one study has shown that Nab2 can enhance Egr1
transactivation. Nab2 phosphorylation could potentially play a role in determining whether or
not Nab2 activates or represses Egr1 independent of Nab2 directly binding to Egr1. In conclusion,
the data presented here provides strong evidence that Nab2 is phosphorylated both basally and
in response to ERK signaling induced by NGF treatment of PC12 cells. This post-translational
modification could have a number of effects on Nab2 and its interactions with other proteins in
the cell. Learning more about the consequence of Nab2 phosphorylation in PC12 cells will be an
interesting project for future members of the Adams lab.
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